Oral Wegovy is here: what the UK's first GLP-1 pill unlocks

The first GLP-1 weight-loss pill went on sale in the UK on Monday. Oral Wegovy is the same semaglutide as the weekly injection, in a tablet. The MHRA cleared it on 11 June for adults with a BMI over 30, or 27 to 30 with a weight-related condition, alongside diet and activity. It launched privately, through Boots and other high street and online pharmacies, and isn't on the NHS yet. Oral semaglutide isn't new to Britain either. It has been prescribed here for type 2 diabetes as Rybelsus for years, which the BMJ noted when the weight-loss version arrived. What's new is the reason people will now ask for it.

The easy headline is that the needles are gone. That's true, and it isn't the interesting part. The injection was never hard to use. What the needle did was sit at the front door, a small moment of hesitation before anyone had felt a result. Take it away and you lower the barrier for the people who stalled there.

I spent eight years building a consumer health brand in a category people felt awkward buying into, and the lesson that took longest to land was that friction at the point of entry is rarely about difficulty. It's about how a product makes someone feel as they reach for it. A tablet you swallow with water asks for less than a box of needles in the bathroom cabinet. So the pill widens the top of the funnel, and the demand was visible before it even launched. The National Pharmacy Association reported that most pharmacies expected high demand, with many already fielding patient questions in the weeks before sale.

A tablet you swallow with water asks for less than a box of needles in the bathroom cabinet.

There's a women's health layer that's easy to miss. The people most affected by an easier way in aren't a general crowd. Menopausal women, whose falling estrogen drives the insulin resistance and midsection weight that a Circulation review describes, are turning to these drugs in large numbers. So are women trying to reach a healthier weight before pregnancy, where even a modest loss can restore ovulation, which is how the fertility literature explains the rise of so-called Ozempic babies. Both groups move on and off these medicines in ways the approval trials never studied. The guidance for anyone trying to conceive is to stop semaglutide weeks before, not something you manage alone off a checkout page. For them, how they start matters, but where they get it matters more.

That's what the launch noise skips. A pill normalises faster than an injection because it looks like everything else in the kitchen drawer. It's easier to post, easier to fold into a pharmacy's existing shelf logic, easier to imagine buying the way you'd buy anything else. And that ease is exactly where the risk moves. When a product this familiar carries this much demand, the fakes follow it. The National Pharmacy Association found that 97% of pharmacies were worried about counterfeit weight-loss pills entering the supply chain. A GLP-1 is a prescription medicine with real effects on the body, including the loss of muscle alongside fat that the trials weren't designed to manage. It is not ibuprofen, and it shouldn't be bought like it.

So the pill is a genuine unlock. It brings in people who hesitated at the injection, and for a lot of them that's a good thing. But easy to swallow is not the same as safe to source. The next phase won't be won by whoever makes starting frictionless. It goes to the credible prescriber and the regulated pharmacy who make sure the person taking it was seen, assessed and supplied properly, and stays seen after the first prescription. The drug was always going to be the easy part. Where you get it is what counts now.